Clinical characteristics associated with development of recurrence and progression in usual-type vulvar intraepithelial neoplasia

International Journal of Gynecological Cancer

Volumn 23, Issue 8, 2013, Pages 1476-1483

  Van Esch, Edith M G ^a   Dam, Maija C I ^a   Osse, Michelle E M ^a   Putter, Hein ^a   Trimbos, Baptist J B M Z ^a   Fleuren, Gertjan ^a   Van Der Burg, Sjoerd H ^a   Van Poelgeest, Mariëtte I E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Immunotherapy; Prognostic factors; Recurrence; UsualVIN (uVIN); Vulvar carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; IMIQUIMOD;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE COURSE; EXCISION; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; LASER SURGERY; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MINIMAL RESIDUAL DISEASE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SMOKING; TOPICAL TREATMENT; TUMOR GROWTH; TUMOR RECURRENCE; USUAL TYPE VULVAR INTRAEPITHELIAL NEOPLASIA; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DISEASE; VAGINA DISEASE; VULVA CARCINOMA; VULVA TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NETHERLANDS; RETROSPECTIVE STUDIES; VULVAR NEOPLASMS; YOUNG ADULT;

EID: 84888209883     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182a57fd6     Document Type: Article

References (43)

1. Sideri M, Jones RW, Wilkinson EJ, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med. 2005;50: 807-810.
2. van de Nieuwenhof HP, van der Avoort IA, de Hullu JA. Review of squamous premalignant vulvar lesions. Crit Rev Oncol Hematol. 2008;68:131-156.
3. Garland SM, Insinga RP, Sings HL, et al. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol Biomarkers Prev. 2009;18:1777-1784.
4. Judson PL, Habermann EB, Baxter NN, et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006;107:1018-1022.
5. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32:S16-S24.
6. Kjellberg L, Hallmans G, Ahren AM, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer. 2000;82:1332-1338.
7. Khan AM, Freeman-Wang T, Pisal N, et al. Smoking and multicentric vulval intraepithelial neoplasia. J Obstet Gynaecol. 2009;29:123-125.
8. Petry KU, Kochel H, Bode U, et al. Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women. Gynecol Oncol. 1996;60:30-34.
9. de Jong A, van der Burg SH, Kwappenberg KM, et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 2002;62:472-479.
10. Welters MJ, de Jong A, van den Eeden SJ, et al. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 2003;63:636-641.
11. van Poelgeest MI, Van Seters M, Van Beurden M, et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res. 2005;11:5273-5280.
12. Bourgault V I, Moyal BM, Berville S, et al. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. Clin Exp Immunol. 2010;159:45-56.
13. Van Seters M, Van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol. 2005;97:645-651.
14. Bourgault Villada I, Moyal BM, Ziol M, et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res. 2004;64:8761-8766.
15. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol. 2005;106:1319-1326.
16. Meeuwis KA, van Rossum MM, van de Kerkhof PC, et al. Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients. Transpl Int. 2010;23:191-199.
17. Van Beurden M, van der Vange N, ten Kate FJ, et al. Restricted surgical management of vulvar intraepithelial neoplasia 3: focus on exclusion of invasion and on relief of symptoms. Int J Gynecol Cancer. 1998;8:73-77.
18. Hillemanns P, Wang X, Staehle S, et al. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol. 2006;100:271-275.
19. Likes WM, Stegbauer C, Tillmanns T, et al. Correlates of sexual function following vulvar excision. Gynecol Oncol. 2007; 105:600-603.
20. Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer. 2010;102: 1129-1136.
21. Winters U, Daayana S, Lear JT, et al. Clinical and immunologic results of a phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin Cancer Res. 2008;14:5292-5299.
22. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361:1838-1847.
23. Davidson EJ, Boswell CM, Sehr P, et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 2003;63: 6032-6041.
24. Van Seters M, Van Beurden M, ten Kate FJ, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med. 2008;358:1465-1473.
25. van Esch EM, Welters MJ, Jordanova ES, et al. Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy. Expert Rev Vaccines. 2012;11:821-840.
26. van den Brule AJ, Pol R, Fransen-Daalmeijer N, et al. GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high-throughput identification of human papillomavirus genotypes. J Clin Microbiol. 2002;40:779-787.
27. Kleter B, van Doorn LJ, Schrauwen L, et al. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999; 37:2508-2517.
28. Kuppers V, Stiller M, Somville T, et al. Risk factors for recurrent VIN. Role of multifocality and grade of disease. J Reprod Med. 1997;42:140-144.
29. Modesitt SC, Waters AB, Walton L, et al. Vulvar intraepithelial neoplasia III: occult cancer and the impact of margin status on recurrence. Obstet Gynecol. 1998;92:962-966.
30. Wallbillich JJ, Rhodes HE, Milbourne AM, et al. Vulvar intraepithelial neoplasia (VIN 2/3): comparing clinical outcomes and evaluating risk factors for recurrence. Gynecol Oncol. 2012;127:312-315.
31. McNally OM, Mulvany NJ, Pagano R, et al. VIN 3: a clinicopathologic review. Int J Gynecol Cancer. 2002;12: 490-495.
32. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A. 2010;107:11895-11899.
33. Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64: 2205-2211.
34. Brown JV, Goldstein BH, Rettenmaier MA, et al. Laser ablation of surgical margins after excisional partial vulvectomy for VIN: effect on recurrence. J Reprod Med. 2005;50:345-350.
35. Terlou A, Van Seters M, Ewing PC, et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. Gynecol Oncol. 2011;121:157-162.
36. Iavazzo C, Pitsouni E, Athanasiou S, et al. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. Int J Gynaecol Obstet. 2008;101:3-10.
37. Ahr A, Rody A, Kissler S, et al. Risk factors for recurrence of vulvar intraepithelial neoplasia III (VIN III). Zentralbl Gynakol 2006; 128:347-351.
38. Chulvis do Val IC, Almeida Filho GL, Valiante PM, et al. Vulvar intraepithelial neoplasia p53 expression, p53 gene mutation and HPV in recurrent/progressive cases. J Reprod Med. 2004;49: 868-874.
39. Jamieson DJ, Paramsothy P, Cu-Uvin S, et al. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet Gynecol. 2006; 107:1023-1028.
40. Hampl M, Wentzensen N, Vinokurova S, et al. Comprehensive analysis of 130 multicentric intraepithelial female lower genital tract lesions by HPV typing and p16 expression profile. J Cancer Res Clin Oncol. 2007;133:235-245.
41. Goffin F, Mayrand MH, Gauthier P, et al. High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. J Med Virol. 2006;78:814-819.
42. Vinokurova S, Wentzensen N, Einenkel J, et al. Clonal history of papillomavirus-induced dysplasia in the female lower genital tract. J Natl Cancer Inst. 2005;97:1816-1821.
43. Hording U, Junge J, Poulsen H, et al. Vulvar intraepithelial neoplasia III: a viral disease of undetermined progressive potential. Gynecol Oncol. 1995;56:276-279.